- CAR-T细胞疗法、TIL疗法、TCR疗法 -
In the past year, the CAR T-cell therapy field has heated up considerably with two recently approved therapies, Kymriah™ and Yescarta™. Efforts to design CAR, TCR and TILs with greater targeting precision, safety profiles and efficacy are leading to a new generation of improved products that will continue to propel the field forward. Come to CHI’s Inaugural Winning Strategies for CAR T, TIL and TCR Therapy track at the PEGS Europe Summit to learn engineering updates, clinical progress and streamlined manufacturing that promise to greatly advance T-cell therapies forward.

Preliminary Agenda


T4 Pan-ERB-Targeted CAR T-Cell Immunotherapy of Head and Neck Cancer: Phase I Trial Results
John Maher, FRCPath, PhD, Consultant & Senior Lecturer, Immunology, Cancer Studies, King’s College London

The Next Generation of CAR T Cells
Hinrich Abken, PhD, Professor, Genetics & Immunology, Center for Molecular Medicine Cologne, University of Cologne

NKG2D CAR T Cell Therapy: Developing an Autologous and Allogeneic CAR T Approach Exploiting the Targeting Capacity of the Innate Immune System
David Gilham, PhD, Vice President, R&D, Celyad

Targeting the Tumour Vasculature with CAR T Cells
Steven P. Lee, PhD, Senior Cancer Research Fellow and Training Lead for the Birmingham CRUK Cancer Centre, Institute of Immunology and Immunotherapy, University of Birmingham

Imaging CAR T-Cells
Sophie Papa, PhD, Senior Lecturer and Honorary Consultant Medical Oncologist, King’s College London

Resistance to Chimeric Antigen Receptor T Cells for Hematological Malignancies
Marco Ruella, MD, Clinical Instructor, Associate Director, Dr. June’s Laboratory, Center for Cellular Immunotherapies (CCI), Perelman School of Medicine, University of Pennsylvania


KEYNOTE PRESENTATION: The ImmTAC Platform: How Far We Have Come and Where We Are Going
Bent K. Jakobsen, PhD, CSO, Immunocore Ltd.

Genetic Engineering of Therapeutic T Cells
Hans J. Stauss, MD, PhD, Director & Professor, Tumor Immunology, Infection & Immunity & Transplantation, Royal Free Hampstead NHS Trust


Adoptive Cell Therapy Based on TILs in the Era of Check Point Inhibitors
Inge Marie Svane, MD, Professor, Director, Center for Cancer Immune Therapy – CCIT, Department of Oncology and Haematology, Herlev Hospital, University of Copenhagen

New Broadly Expressed Cancer Targets from Successful TIL Therapy
Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Infection & Immunity, Cardiff University School of Medicine

PANEL DISCUSSION: Cellular Therapy vs. Soluble (Antibody and TCR)
Moderator: Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Infection & Immunity, Cardiff University School of Medicine


Safety Challenges of T Cell Therapies: The Balance between Efficacy and Safety
Michaela Sharpe, PhD, Head of Nonclinical Safety and Immunotherapy Strategy, Cell and Gene Therapy Catapult

Targeting the T Cell Receptor β-Chain Constant Region for Immunotherapy of T Cell Malignancies
Paul Maciocia, PhD, Clinical Training Fellow/BRC Clinical Lecturer in Haematology, Research Department of Haematology, Faculty of Medical Sciences, University College London

CAR T Cells –What's Next? From Personalized to "Off the Shelf" CARs
Anat Globerson Levin, PhD, Senior Researcher & Immunology Lab Manager; Immunology Research Lab, Tel-Aviv Sourasky Medical Center

PANEL DISCUSSION: Cell Therapy: Making It an "Off the Shelf" Therapy
Moderator to be Announced

Sponsored Presentation

Target Specificity Screening of CAR T Cells using Human Cell Microarray Technology
Mark Aspinall-O'Dea, EMEA, Business Development Manager, Retrogenix Limited

* 活动内容有可能不事先告知作更动及调整。

Choose your language